Novavax (NVAX) Tops Q2 EPS by 12c, Revenues Miss

August 10, 2020 4:33 PM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Novavax (NASDAQ: NVAX) reported Q2 EPS of ($0.30), $0.12 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $35.54 million versus the consensus estimate of $39.58 million.

“Novavax’ unprecedented development activities for NVX-CoV2373 and progress continued through the second quarter,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “Since identifying a candidate vaccine to address the COVID-19 pandemic in March, we’ve secured significant funding, implemented global manufacturing capacity and completed and reported our successful Phase 1 trial. We’ve also expanded our senior leadership team to advance our efforts to bring NVX-CoV2373 to market as rapidly as possible and grow our infrastructure to support commercial stage operations.”

For earnings history and earnings-related data on Novavax (NVAX) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Earnings, Management Comments

Related Entities

Earnings